PMCB

PMCB is the ticker symbol for PharmaCyte Biotech, Inc., a biotechnology company that focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. The company’s lead product candidate is CYT-006, a cell therapy that is being developed for the treatment of metastatic pancreatic cancer. PharmaCyte Biotech is also developing CYT-007, a cell therapy for the treatment of type 1 diabetes.